Insulet (NASDAQ:PODD) Given “Outperform” Rating at Royal Bank Of Canada

Insulet (NASDAQ:PODD)‘s stock had its “outperform” rating restated by equities research analysts at Royal Bank Of Canada in a research report issued on Wednesday,Benzinga reports. They presently have a $280.00 target price on the medical instruments supplier’s stock. Royal Bank Of Canada’s target price points to a potential upside of 94.41% from the company’s current price.

PODD has been the subject of several other reports. Rothschild & Co Redburn reissued a “neutral” rating and issued a $220.00 price target (down from $380.00) on shares of Insulet in a report on Friday, April 24th. Jefferies Financial Group dropped their price objective on Insulet from $400.00 to $360.00 in a research note on Thursday, May 7th. Weiss Ratings cut Insulet from a “hold (c)” rating to a “hold (c-)” rating in a research report on Friday, May 15th. Sanford C. Bernstein decreased their target price on Insulet from $330.00 to $200.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Finally, Oppenheimer lowered their price target on Insulet from $300.00 to $210.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Twenty-one research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $252.48.

Insulet Stock Performance

PODD stock traded down $9.78 during midday trading on Wednesday, reaching $144.03. 627,610 shares of the company’s stock traded hands, compared to its average volume of 1,134,362. The firm has a market capitalization of $9.98 billion, a PE ratio of 33.49, a price-to-earnings-growth ratio of 1.23 and a beta of 1.20. The company has a 50-day moving average price of $188.59 and a two-hundred day moving average price of $248.51. Insulet has a 52 week low of $141.02 and a 52 week high of $354.88. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, beating the consensus estimate of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company had revenue of $761.70 million during the quarter, compared to analysts’ expectations of $729.89 million. During the same period in the previous year, the business earned $1.02 earnings per share. The firm’s quarterly revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, equities analysts anticipate that Insulet will post 6.43 EPS for the current year.

Institutional Trading of Insulet

A number of hedge funds have recently bought and sold shares of the company. Larson Financial Group LLC grew its position in Insulet by 114.6% during the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. purchased a new stake in shares of Insulet in the 4th quarter valued at $26,000. Elyxium Wealth LLC bought a new position in shares of Insulet during the 4th quarter valued at $28,000. DV Equities LLC purchased a new position in Insulet in the 4th quarter worth $28,000. Finally, MV Capital Management Inc. purchased a new position in Insulet in the 4th quarter worth $29,000.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.